PERSPECTA

News from every angle

← Back to headlines

UBS Maintains 'Neutral' Rating on GSK Ahead of CEO Strategy Update

UBS has reiterated its 'neutral' rating for GSK, with investors and analysts focusing on the upcoming strategy update from the pharmaceutical company's chief executive.

13 Jul, 13:25 — 13 Jul, 13:25
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual33d ago

UBS keeps GSK at 'neutral' with focus on chief executive's strategy update

Read full article →

Related Stories

Iran Attacks Tanker in Strait of Hormuz Amid Rising Tensions

1h ago

Luigi Mangione Pleads Guilty to Killing UnitedHealthcare CEO

1h ago

Old-School Investing Strategies Remain Relevant in Age of AI

1h ago

Bijelo Polje Company and Turkish Citizen Face Tax Evasion Charges

2h ago